<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04407234</url>
  </required_header>
  <id_info>
    <org_study_id>17376</org_study_id>
    <secondary_id>I8F-MC-GPHU</secondary_id>
    <nct_id>NCT04407234</nct_id>
  </id_info>
  <brief_title>A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide</brief_title>
  <official_title>The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how tirzepatide affects stomach emptying in
      overweight/very overweight participants. Participants include those without diabetes and
      those with type 2 diabetes.

      The study will last about 13 weeks for each participant, including screening.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">March 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time of Maximum Concentration (Tmax) of Acetaminophen</measure>
    <time_frame>Pre-dose through 36 hours post-dose on Day-1</time_frame>
    <description>PK: Tmax of Acetaminophen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Tmax of Acetaminophen</measure>
    <time_frame>Pre-dose through 36 hours post-dose on Day 2</time_frame>
    <description>PK: Tmax of Acetaminophen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Tmax of Acetaminophen</measure>
    <time_frame>Pre-dose through 36 hours post-dose on Day 37</time_frame>
    <description>PK: Tmax of Acetaminophen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Pre-dose through 9 weeks</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC(0-tlast) of Tirzepatide at Steady State</measure>
    <time_frame>Pre-dose through 9 weeks</time_frame>
    <description>PK: AUC(0-tlast) of Tirzepatide at Steady State</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Tirzepatide at Steady State</measure>
    <time_frame>Pre-dose through 9 weeks</time_frame>
    <description>PK: Cmax of Tirzepatide at Steady State</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Tirzepatide + Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Tirzepatide administered SC.</description>
    <arm_group_label>Tirzepatide + Acetaminophen</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen administered orally.</description>
    <arm_group_label>Tirzepatide + Acetaminophen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index (BMI) between 27 to 45 kilograms per meter squared (kg/mÂ²),
             inclusive at screening

          -  For nondiabetic subjects: as determined by medical history, physical examination, and
             safety assessments at screening

          -  For participants with a confirmed type 2 diabetes diagnosis: The condition must be
             managed either by diet and exercise alone or on a stable dose of metformin for the
             past 3 months

          -  Willing and agreeable to commit to the duration of the study and undergo study
             procedures as instructed by the clinic staff

        Key Exclusion Criteria

          -  Have undergone gastric bypass or bariatric surgery

          -  Have received prescription drugs or over the counter drugs that promote weight loss in
             the past 6 months prior to screening

          -  For participants with a confirmed type 2 diabetes diagnosis: Have experienced more
             than 1 episode of severe low blood sugar that require emergency treatment,
             hospitalization or third parties to administer rescue treatment, in the past 6 months

          -  Have any lifetime history of a suicide attempt

          -  Have other medical conditions or medical history that make participation in the study
             unsafe or which may interfere in the interpretation of the results of the study

          -  Unwilling to comply with smoking and alcohol restrictions during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>305-817-2900</phone>
    </contact>
    <investigator>
      <last_name>Juan C Rondon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/2VTN9N9xaJ4FhSAZuwJdif?conditionId=1wecF0AgauDdWnqHV7GJGP</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

